Recombinant Activated Factor VII Infusion Improves Outcome of Parturient with Intractable Postpartum Hemorrhage
|Full paper||Not Available|
This prospective selective mullicenler study aimed to evaluate the outcome of parturient with intractable postpartum hemorrhage (PPH) after administration of recombinant activated factor VII (rFVIIa). Patients & Methods: All patients were admitted to ICU for preliminary evaluation and first aid support. Data concerning haemostatic surgical procedures and transfused amounts of packed red blood cells (PC), fresh frozen plasma (FFP) or platelet (Plat) were recoded. Patients were infused with rFVIIa in a dose of 90 pg/kg and the response was observed for 15-30 minutes if necessary an additional dose of 30pg/kg was infused and in extreme cases a third dose of 30 pg/kg was given. The need and amount of transfusion of blood products and 48-hrs and I5-days mortality rates were determined. Blood samples were obtained before and after rFVIIa infusion for determination of coagulation profile including prothrombin time (PT), activated partial thromboplastin time (aPTT), Platelet count (Pit) and fibrinogen concentration. Each parameter was scored according to the degree of abnormality and their total score was categorized into three levels of coagulopathy: 0= "none-mild, 1-3= moderate and 4-8= severe.